|
|||||
|
|
||||||
Erratum
for
Jones et al., © 2007 American Society of Clinical Oncology. DOI: 10.1200/JCO.2007.11.9602
ERRATUMThe December 1, 2006, article by Jones et al, entitled "Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer," (J Clin Oncol 24:5381-5387, 2006) requires clarification.In the Patients and Methods section, under Study Design, the second sentence was given as: "Patients were randomly assigned to four cycles of either standard-dose AC (60 and 600 mg/m2, respectively) or TC (75 and 600 mg/m2, respectively) administered by intravenous bolus on day 1 of each 21-day cycle for four cycles as adjuvant treatment after complete surgical excision of the primary tumor (Fig 1)." Whereas it should have read: "Patients were randomly assigned to four cycles of either standard-dose AC (60 and 600 mg/m2, respectively) or TC (75 and 600 mg/m2, respectively) administered by intravenous infusion over 30 to 60 minutes on day 1 of each 21-day cycle for four cycles as adjuvant treatment after complete surgical excision of the primary tumor (Fig 1)." In the Patients and Methods section, under Treatment, the fourth sentence was given as: "AC (60 and 600 mg/m2, respectively) or TC (75 and 600 mg/m2, respectively) was administered by intravenous bolus on day 1 of each 21-day cycle." Whereas it should have read: "AC (60 and 600 mg/m2, respectively) or TC (75 and 600 mg/m2, respectively) was administered by intravenous infusion over 30 to 60 minutes on day 1 of each 21-day cycle." The online version has been corrected in departure from the print.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|